Amyris company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

amyris.com

Founded Year

2003

Stage

PIPE - II | IPO

Total Raised

$341.6M

Market Cap

0.77B

Stock Price

2.31

Revenue

$0000 

About Amyris

Amyris (NASDAQ: AMRS) is building an integrated renewable products company by applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. Amyris Brasil, a subsidiary of Amyris, oversees the establishment and expansion of Amyris's production in Brazil, including SMA Industria Quimica, its joint venture with Sao Martinho. In addition, Amyris is building fuel distribution capabilities in the United States through its subsidiary, Amyris Fuels.

Amyris Headquarter Location

5885 Hollis Street Suite 100

Emeryville, California, 94608,

United States

510-450-0761

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Amyris

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Amyris in 2 CB Insights research briefs, most recently on May 25, 2021.

Expert Collections containing Amyris

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Amyris is included in 3 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

687 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

R

Renewable Energy

2,801 items

Includes companies working on technology to support renewable energy generation.

C

Cannabis

3,834 items

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.

Amyris Patents

Amyris has filed 133 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • Genetics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/27/2019

4/26/2022

Alkanols, Designer drugs, Fatty alcohols, Cannabinoids, Biotechnology

Grant

Application Date

6/27/2019

Grant Date

4/26/2022

Title

Related Topics

Alkanols, Designer drugs, Fatty alcohols, Cannabinoids, Biotechnology

Status

Grant

Latest Amyris News

Global Synthetic Biology Market to Surpass US$ 100.4 Billion by 2030, Says Coherent Market Insights (CMI)

May 19, 2022

Regional Analysis North America (US, Canada), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Europe (U.K, Germany, Italy, France, Spain, Russia and Rest of Europe), APAC (China, Japan, India, South Korea, Australia, ASEAN and Rest of Asia Pacific), ME (GCC Countries, Israel, and Rest of Middle East) & Africa (South Africa, North Africa and Central Africa) Key Companies Covered Thermo Fisher Scientific, Synbio Technologies, Merck KGaA, Agilent Technologies, Inc., GenScript, Amyris, Eurofins Genomics GmbH, Integrated DNA Technologies, Inc., Codexis, Inc., EnBiotix, Inc., Synthego, New England Biolabs (UK) Ltd., Scarab Genomics, LLC and Genomatica, Inc. Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/112 Among product, the enzymes segment is expected to witness the largest market share in the global synthetic biology market over the forecast period. Enzyme engineering plays a central role in the development of effective biocatalysts for biological sciences and biomedicine. This is anticipated to drive the growth of market. In terms of technology, the gene synthesis segment accounted for a major share of the market in 2020. Gene synthesis is emerging technology that enabled to develop innovations in synthetic biology. This is expected to drive the growth of segment Among end user, the biotechnology & pharmaceutical industry segment is expected to hold a dominant position in the market during the forecast period. Increase in focus on developing cell based therapies by pharmaceutical key players is likely propel the segment growth. Among region, North America is expected to dominate the global synthetic biology market over the forecast period. The early adoption of advanced technologies and presence of key market players are the factors anticipated to drive the market growth in the region. Competitive Landscape: Key players operating in the global synthetic biology market include Thermo Fisher Scientific, Synbio Technologies, Merck KGaA, Agilent Technologies, Inc., GenScript, Amyris, Eurofins Genomics GmbH, Integrated DNA Technologies, Inc., Codexis, Inc., EnBiotix, Inc., Synthego, New England Biolabs (UK) Ltd., Scarab Genomics, LLC, and Genomatica, Inc. Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/112 Market Segmentation: Oligonucleotides Related Market Intelligence Reports: Oligonucleotide Synthesis Market , by Equipment & Services (Equipment/Synthesizer, Reagents, and Services (Oligo Synthesis, Modification, and Purification)), by Technology (Column-based, and Microarray-based), by Nucleic Acid (DNA and RNA), by Application (Drug Discovery and Therapeutics), by End User (Academic Research Institutes, Diagnostic Laboratories, and Pharmaceutical-Biotechnology Companies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027 Biologics Market , by Drug Class (Monoclonal Antibody, Vaccine, Recombinant Insulin, Human Growth Hormone, Blood Factor, Fusion Protein, Erythropoietin, Recombinant Enzyme, Interferon, Colony-stimulating Factor, Cell Therapy, Gene Therapy, Oligonucleotides and Others (Peptide, Botulinum Toxin, and Others)), by Therapeutic Application (Oncology, Metabolic Disorders, Autoimmune/Immunologic Diseases, Ophthalmic Diseases, Inflammatory Bowel Diseases (IBDs), Respiratory Disorders, Neurological Disorders, Musculoskeletal Disorders (MSDs), Cardiovascular Diseases (CVDs), Infectious Diseases, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027 About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Amyris Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Amyris Rank

  • When was Amyris founded?

    Amyris was founded in 2003.

  • Where is Amyris's headquarters?

    Amyris's headquarters is located at 5885 Hollis Street, Emeryville.

  • What is Amyris's latest funding round?

    Amyris's latest funding round is PIPE - II.

  • How much did Amyris raise?

    Amyris raised a total of $341.6M.

  • Who are the investors of Amyris?

    Investors of Amyris include Thayer Ventures and SVG Ventures.

  • Who are Amyris's competitors?

    Competitors of Amyris include Viridos, Enerkem, Erbi Biosystems, Lynntech, Gevo and 13 more.

You May Also Like

Viridos Logo
Viridos

Viridos is dedicated to developing and commercializing genomic-driven solutions to address global energy and environmental challenges. The company's main research and business programs are focused on the following major bioenergy areas: designing advanced biofuels with superior properties compared to ethanol and biodiesel; harnessing photosynthetic organisms to produce value-added products directly from sunlight and carbon dioxide; developing new biological solutions to increase production and/or recovery rates of subsurface hydrocarbons and developing high-yielding, more disease resistant and economic feedstocks. It was founded in 2005 and is based in La Jolla, California.

Erbi Biosystems Logo
Erbi Biosystems

Erbi Biosystems is developing systems to automate the study of microorganisms for basic research and bioprocess characterization and optimization. Through microfluidics and integration, large scale bioreactors can be miniaturized to the milliliter scale, enabling greatly reduced volumes in addition to automated control.

W
WHEB Biofuels

WHEB Biofuels Limited aims to be a biofuels producer that also invests in biofuels technologies

B
Biodiesel Technologies

Biodiesel Technologies offers biodiesel processor equipment

B
Biofuel Industries Group

NextDiesel biodiesel and Biofuel Industries Group are producers of high grade B100 biodiesel fuel

A
Altra Biofuels

Formed as Malibu Capital Partners, Inc., Altra has been in the business of acquiring and developing a portfolio of renewable energy projects throughout the United States specifically focused on the production and sale of ethanol and biodiesel. Altra aims to become the leading integrated biofuels company in the U.S., employing state-of-the-art manufacturing facilities, processing technologies and customer service disciplines, and positioned as a critical biofuels supplier to petroleum companies and other significant end-users in all key geographic markets.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.